Fairfax Media is moving forward with a lawsuit against Network Ten over the alleged infringement of its “Boss” trade mark, even after the TV broadcaster agreed to stop using the name.
Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on “hearsay and speculation,” Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world’s best-selling vaccine.
US-based chemical and materials technology company Cytec Industries has filed a patent lawsuit against a unit of Ecolab, after a delegate for IP Australia gave the water technology company a third chance to amend its patent for preventing sediment buildup on mining equipment.
Ceramic tile maker Ceramiche Caesar has appealed a judge’s decision allowing building products maker Caesarstone to register two trade marks that are deceptive similarity to one of its marks, with the judge finding Caesarstone had shown honest concurrent use of the marks.
Generic drug maker Sun Pharma has emerged victorious in a lawsuit brought against it by Mylan relating to Sun’s plans to launch a generic version of cholesterol drug fenofibrate.
Businessman Clive Palmer has successfully registered the United Australia Party name with the corporate regulator in what appears to be a settlement of his trade mark infringment suit against the expelled directors of another political party who had adopted the coveted moniker two years ago.
Denmark-based Lundbeck cannot recover damages for the alleged infringement of its Lexapro patent by generic drug companies that it dropped its claims against, a judge has found.
The Full Federal Court has shot down a challenge by Japanese electronics company Nichia Corp. to a ruling that Arrow Electronics did not infringe its patent for a white light emitting device.
The CSIRO is appealing a decision by the Commissioner of Patents that allowed chemical giant BASF to amend its application for a genetically modified organisms patent.
Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.